CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

QNCXQuince Therapeutics, Inc.

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $31.01 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$31.54M
CountryUSA
RECENT INSIDER TRADES
  • 2025-12-29 · Benatti Luca (Director) · SELL
INSTITUTIONAL OWNERSHIP
Institutional holders30
Shares held3,620,735
Value$26.18M
As of quarter end2026-06-30
RECENT NEWS
  • Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001
  • Raymond James initiates Quince Therapeutics stock coverage with outperform rating
  • Quince Therapeutics holds shareholder and analyst call
  • Quince Therapeutics, Inc. Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
  • Quince Therapeutics hosts KOL event on PH-ILD and BOS treatments
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
Quince Therapeutics, Inc. (QNCX) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit